research Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
Search
for
Sort by
Research
210-240 / 1000+ results research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research BI02 (P97): Epidermal growth factor receptor inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege
research Experiences with Smo antagonist vismodegib for the treatment of locally advanced basal cell carcinoma
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
research Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
research A case of atopic dermatitis with self‐healing acute diffuse and total alopecia during nemolizumab treatment
research Folliculitis decalvans managed with adalimumab: A case report
Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.
research Editorial: Targeted immunological therapies in dermatology
Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.
research 600 Impact of baricitinib on work productivity and indirect costs in adult patients with atopic dermatitis: A meta-analysis of clinical trials
Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
research 41261 Identification of Demographic and Clinical Features Associated with Multi-Biologic Failure in the CorEvitas Psoriasis Registry
Certain factors like being female, having high cholesterol, using Medicaid, and previous non-biologic treatments increase the risk of multiple biologic failures in psoriasis patients.
research Dupilumab: A Review of Present Indications and Off-Label Uses
Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
research Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch
The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.
research 1117 PX-12 inhibits NLRP3 inflammasome activation to treat psoriasis
PX-12 may help treat psoriasis by blocking inflammation and cell death.
research Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
research The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata
Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
research A case of recurrent acute pancreatitis following ocrelizumab use
Ocrelizumab may cause pancreatitis in some patients.
research USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy
Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
research Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research Rare Cutaneous Side Effects of Imiquimod: A Review on Its Mechanisms, Diagnosis, and Management
Imiquimod can cause rare skin side effects, some irreversible, and long-term follow-up is important for users.
research Three-dimensional imaging for facial vitiligo: Results from a phase 2 randomized controlled trial investigating upadacitinib in patients with vitiligo
3D imaging effectively tracks skin changes in vitiligo treatment.
research Impact of ustekinumab on quality of life and sexual difficulties associated with psoriasis: Results from phase III clinical trials
Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.
research 574 Comparative analysis of quality of life impact in patients with autoimmune blistering disease
Patients with autoimmune blistering diseases experience a reduced quality of life, with the need for better measurement tools, especially for those with mucous membrane pemphigoid.
research A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment
Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata
Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.
research Successful Dupilumab Administration in Adolescent with Alopecia Areata and Atopic Dermatitis: Clinical Case
Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.
research P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.